Clinical trials: Buprenorphine
Spinal Stenosis, Pain, Postoperative
Postoperative Analgesia With Buprenorphine for Postoperative Pain Control and Quality of Life After Spinal Surgery
Major purpose of this research is to evaluate the effect and usefulness of Buprenorphine transdermal system (MTDS) among the patients with lumbar spinal disease who was performed the single-level posterior lumbar fusion.
- Trial name
- NCT02416804
- Testing
- Buprenorphine, Tramadol
- Where
- South Korea
- Volunteers
- 69 people
- Sponsor
- Seoul National University Hospital
Hepatitis C, Chronic
Buprenorphine Versus Methadone Maintenance in Hepatitis C Patients Receiving Peg-Intron and Rebetol (Study P04279)(TERMINATED)
This randomized, single-center, controlled study is designed to evaluate the safety, tolerability, and efficacy of treatment with Peg-Intron with Rebetol in methadone or buprenorphine maintenance patients with hepatitis C.
- Trial name
- NCT00279565
- Testing
- buprenorphine, methadone, pegylated interferon alfa-2b plus ribavirin
- Volunteers
- 128 people
- Sponsor
- Indivior Inc.
Opioid-use Disorder, Opioid Use, Unspecified
Opioid Use Disorder in Pregnancy in Long-Term Maternal/Infant Outcomes
The objective of this study is to better understand the comprehensive integration of both clinical and genetic factors that will help to identify mothers who could be at an increased risk of poor response to opioid substitution…
- Conditions
- Opioid-use Disorder, Opioid Use, Unspecified, Buprenorphine Dependence
- Trial name
- Mother/BabyOUD (NCT03923374)
- Testing
- Subutex / Buprenorphine, Fetal & Neonatal MRI, DNA/Genetic/Pharmacokenetic Blood Draws
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Senthil Sadhasivam
Neonatal Abstinence Syndrome, Neonatal Opiate Withdrawal Syndrome
Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure
Neonatal withdrawal syndrome is a series of signs and symptoms in infants exposed to opioids in utero. Buprenorphine has demonstrated a 40% reduction in length of pharmacologic treatment compared to oral morphine.
- Trial name
- B-PHORE (NCT03608696)
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Thomas Jefferson University
Opioid-use Disorder, Chronic Pain
Randomized Trial of ACT and a Care Management App in Primary Care-based Buprenorphine Treatment
The proposed IMPOWR Research Center at Montefiore-Einstein (IMPOWR-ME) will create a multidisciplinary and synergistic program of research to test multimodal treatments that address both chronic pain and opioid use disorder.
- Trial name
- NCT05039554
- Testing
- Acceptance and commitment therapy, Valera Smartphone Application, Treatment as Usual
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Albert Einstein College of Medicine
Chronic Pain, Pain
Virtual Empowered Relief for Chronic Pain
The purpose of the current pilot study is to examine a feasibility and the preliminary efficacy of Empowered Relief (ER) class when it is delivered 'virtually' to patients with chronic pain who take methadone or buprenorphine.
- Trial name
- NCT05057988
- Testing
- Empowered Relief class
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Stanford University
Opioid-use Disorder
Contingency Management to Enhance Office-Based Buprenorphine Treatment
Contingency Management interventions provide incentives to substance abuse patients when patients meet therapeutic goals. This project will compare the effectiveness of two Contingency Management interventions (which the…
- Trial name
- NCT04024059
- Testing
- Contingency Management for adherence, Contingency Management for abstinence
- Where
- United States
- Volunteers
- 375 people
- Sponsor
- Johns Hopkins University
Opioid-use Disorder
Examining an Adaptive Approach to Providing Psychosocial Support to Buprenorphine Patients
The purpose of this study is to address important knowledge gaps regarding the optimal way to provide psychosocial treatment to patients who are receiving buprenorphine for opioid use disorder (OUD) in office-based settings.
- Trial name
- NCT04650386
- Testing
- Psychosocial support determined by adaptive treatment algorithm
- Where
- 2 sites in United States
- Volunteers
- 125 people
- Sponsor
- Public Health Management Corporation
Depression
Study Assessing the Safety and Therapeutic Effect of Buprenorphine in MDD Patients
The primary objective of this study is to assess the therapeutic effect of Buprenorphine in MDD population. The secondary objectives of this study are to assess the therapeutic effect, the feasibility and safety of buprenorphine…
- Trial name
- NCT01311570
- Testing
- Buprenorphine
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Shalvata Mental Health Center
Opioid Use Disorder
Measurement-Based Care to Support Buprenorphine-Naloxone Treatment in Outpatient Addiction Clinics
People receiving buprenorphine-naloxone (bup-nx) for opioid use disorder often face changes in cravings, withdrawal, and return to use risk between clinic visits, but their care team may not know about these changes until the…
- Trial name
- Bup-MBC (NCT07839182)
- Testing
- Bup-MBC
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Vanderbilt University Medical Center
Opioid-Related Disorders
Clonidine for Relapse Prevention in Buprenorphine-Maintenance Patients
Background: Though the drug buprenorphine effectively treats dependence on opioids like heroin, some abstinent patients relapse to use during treatment.
- Trial name
- NCT00295308
- Testing
- Clonidine
- Where
- United States
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Opioid-use Disorder
Coordinating Opioid Use Treatment Through Medical Management With Infection Treatment (Project COMMIT)
This study seeks to test a new model of care (ID/LAB) in which opioid use disorder (OUD) is managed by infectious disease (ID) specialists and hospitalists concurrent with management of the OUD-related infections, using…
- Trial name
- COMMIT (NCT04180020)
- Testing
- ID/LAB, TAU
- Where
- 3 sites in United States
- Volunteers
- 171 people
- Sponsor
- Yale University
Opiate Addiction
Examination of Cognitive Function in Patients Treated With Subutex
People who addicted to Heroin and other opiates suffer from a disease with approved genetic basis. It causes to a behavioral response as searching and using those drugs even though they know it causes severe damages as…
- Trial name
- NCT00687089
- Testing
- Sexual, cognitive functional tests and measurement weight
- Volunteers
- 60 people
- Sponsor
- BeerYaakov Mental Health Center
Opioid Dependence
A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence
This study will measure the amount of buprenorphine found in the blood after taking sublingual buprenorphine tablets versus after implantation with 4 Probuphine (buprenorphine implants).
- Trial name
- PRO-810 (NCT00768482)
- Testing
- Probuphine (buprenorphine implant), Sublingual Buprenorphine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Titan Pharmaceuticals
Smoking Cessation
A Pilot Text Messaging Intervention to Reduce Smoking in Office-based Buprenorphine and Inpatient Detoxification Patients
The primary purpose of this study is to understand the feasibility of a text messaging intervention developed by the National Cancer Institute, known as Smokefreetxt, to improve smoking cessation among opiate and/or alcohol…
- Trial name
- NCT02665208
- Testing
- Treatment As Usual (TAU), Nicotine Replacement Therapies, Text Message Intervention (TMI)
- Where
- United States
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Opioid Use Disorder
Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder
Open-label multi-center, 48 week safety study, consistent with standard practice for long-term safety studies. This one year safety study will utilize CAM2038 q1w (once weekly) and q4w (once monthly) and will have 3 phases…
- Trial name
- NCT02672111
- Testing
- CAM2038 q1w or q4w exposure to SL BPN/NX, CAM2038 q1w or q4w new to BPN treatment
- Where
- 32 sites in United States, Australia and 6 more
- Volunteers
- 228 people
- Sponsor
- Braeburn Pharmaceuticals
Opioid-use Disorder
Buprenorphine as Adjunct to Outpatient Induction Onto Vivitrol
The study will enroll 30 opioid-dependent participants into an open-label pilot outpatient study of methods to facilitate induction and stabilization onto XR-NTX.
- Trial name
- NCT03113409
- Testing
- Buprenorphine, Naltrexone, Vivitrol
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Healthy
A Study of the Abuse Liability Potential of ALKS 5461 in Healthy, Non-Dependent, Recreational Opioid Users
This study will evaluate the abuse potential of ALKS 5461.
- Trial name
- NCT02413281
- Testing
- ALKS 5461, Buprenorphine
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Alkermes, Inc.
Adult Opioid-Dependence
Applying Web Technology to Buprenorphine Treatment
The purpose of this clinical trial is to examine the efficacy and cost-effectiveness of an interactive, computer-based psychoeducational system when used by opioid-dependent patients in office-based buprenorphine treatment.
- Trial name
- NCT00182598
- Testing
- computer-based psychoeducational intervention, community-based substance abuse counseling
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- National Development and Research Institutes, Inc.
Opioid Use Disorder, Pregnancy Related
Open Trial of Technology-Enhanced Behavioral Intervention for Buprenorphine Retention in Pregnant and Postpartum People
This study involves testing how useful a technology-enhanced intervention is for pregnant people prescribed buprenorphine for the management of opioid use disorder.
- Trial name
- NCT06496230
- Testing
- Empowering Pregnant Women and People Receiving Medications for Opioid Use Disorder
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Medical University of South Carolina